FY2021 EPS Estimates for Intercept Pharmaceuticals, Inc. Decreased by B. Riley (NASDAQ:ICPT)

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) – Equities researchers at B. Riley reduced their FY2021 earnings estimates for shares of Intercept Pharmaceuticals in a research note issued on Monday, January 10th. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will post earnings of ($3.42) per share for the year, down from their previous estimate of ($3.36). B. Riley has a “Buy” rating and a $30.00 price objective on the stock. B. Riley also issued estimates for Intercept Pharmaceuticals’ Q4 2021 earnings at ($1.24) EPS, Q1 2022 earnings at ($0.69) EPS, Q2 2022 earnings at ($0.96) EPS, Q3 2022 earnings at ($1.24) EPS, Q4 2022 earnings at ($1.40) EPS, FY2022 earnings at ($4.30) EPS, FY2023 earnings at ($1.46) EPS and FY2024 earnings at $4.51 EPS.

Several other equities research analysts also recently commented on the company. Jefferies Financial Group reaffirmed a “hold” rating and set a $19.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, November 5th. Raymond James upped their target price on Intercept Pharmaceuticals from $40.00 to $44.00 and gave the stock an “outperform” rating in a research report on Thursday, November 4th. BMO Capital Markets reissued a “hold” rating and set a $22.00 price objective on shares of Intercept Pharmaceuticals in a report on Monday, November 8th. Finally, Zacks Investment Research lowered Intercept Pharmaceuticals from a “hold” rating to a “sell” rating and set a $17.00 price objective on the stock. in a report on Thursday. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $29.19.

NASDAQ:ICPT opened at $17.76 on Thursday. The stock has a market cap of $524.75 million, a price-to-earnings ratio of -5.48 and a beta of 1.42. The business has a fifty day moving average of $16.83 and a 200-day moving average of $16.50. Intercept Pharmaceuticals has a 1 year low of $11.60 and a 1 year high of $38.94.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Wednesday, November 3rd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.00) by $0.89. The firm had revenue of $92.80 million during the quarter, compared to the consensus estimate of $83.04 million. Intercept Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.01) earnings per share.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisory Services Network LLC bought a new position in shares of Intercept Pharmaceuticals during the 2nd quarter worth about $42,000. Nisa Investment Advisors LLC increased its stake in shares of Intercept Pharmaceuticals by 1,072.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,045 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 3,700 shares during the last quarter. Metropolitan Life Insurance Co NY increased its stake in shares of Intercept Pharmaceuticals by 98,837.5% during the 2nd quarter. Metropolitan Life Insurance Co NY now owns 7,915 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 7,907 shares during the last quarter. Panagora Asset Management Inc. grew its stake in Intercept Pharmaceuticals by 2,542.4% in the 2nd quarter. Panagora Asset Management Inc. now owns 8,482 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 8,161 shares in the last quarter. Finally, Inspire Advisors LLC purchased a new position in Intercept Pharmaceuticals in the 3rd quarter valued at approximately $171,000. Institutional investors and hedge funds own 75.53% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.

Featured Article: Oversold

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.